GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » EV-to-FCF

Albireo Pharma (FRA:BDQM) EV-to-FCF : -6.37 (As of May. 18, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Albireo Pharma's Enterprise Value is €698.39 Mil. Albireo Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2022 was €-109.70 Mil. Therefore, Albireo Pharma's EV-to-FCF for today is -6.37.

The historical rank and industry rank for Albireo Pharma's EV-to-FCF or its related term are showing as below:

FRA:BDQM' s EV-to-FCF Range Over the Past 10 Years
Min: -13.27   Med: -3.58   Max: -0.83
Current: -6.41

During the past 13 years, the highest EV-to-FCF of Albireo Pharma was -0.83. The lowest was -13.27. And the median was -3.58.

FRA:BDQM's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 8.34 vs FRA:BDQM: -6.41

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-05-18), Albireo Pharma's stock price is €41.41. Albireo Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was €-6.362. Therefore, Albireo Pharma's PE Ratio (TTM) for today is At Loss.


Albireo Pharma EV-to-FCF Historical Data

The historical data trend for Albireo Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma EV-to-FCF Chart

Albireo Pharma Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.29 -4.79 -3.60 -4.70 -1.96

Albireo Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.86 -1.96 -3.46 -1.91 -1.53

Competitive Comparison of Albireo Pharma's EV-to-FCF

For the Biotechnology subindustry, Albireo Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Albireo Pharma's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albireo Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Albireo Pharma's EV-to-FCF falls into.



Albireo Pharma EV-to-FCF Calculation

Albireo Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=698.393/-109.699
=-6.37

Albireo Pharma's current Enterprise Value is €698.39 Mil.
Albireo Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-109.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Albireo Pharma  (FRA:BDQM) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Albireo Pharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=41.41/-6.362
=At Loss

Albireo Pharma's share price for today is €41.41.
Albireo Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.362.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Albireo Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Albireo Pharma (FRA:BDQM) Business Description

Traded in Other Exchanges
N/A
Address
53 State Street, 19th Floor, Boston, MA, USA, 02109
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines